DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on March 1, 2006; DOI: 10.1124/dmd.105.007898

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.007898v1
34/6/955    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Dan W Rurak
Nancy Gruber
K Wayne Riggs
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Au Yeung, S. C.
Right arrow Articles by Riggs, K W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Au Yeung, S. C.
Right arrow Articles by Riggs, K W.


Received for publication October 18, 2005.
Revised February 23, 2006.
Accepted for publication February 24, 2006.

A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: Potential involvement of a carrier-mediated mechanism

Sam CS Au Yeung 1, Dan W Rurak 2, Nancy Gruber 2, K Wayne Riggs 2*

1 Quintiles, Inc. 2 University of British Columbia

* Address correspondence to: E-mail: riggskw{at}interchange.ubc.ca

Abstract

The purpose of this study was to examine the disposition of diphenydramine (DPHM) across the ovine blood-brain barrier (BBB). In 6 adult sheep we characterized the CNS pharmacokinetics of DPHM in brain extracellular fluid (ECF) and cerebrospinal fluid (CSF) using microdialysis in 2 experiments. In the first experiment, DPHM was administered via a 5-step i.v infusion (1.5, 5.5, 9.5, 13.5, and 17.5 µg/kg/min; 7 h per step). Average steady-state CNS/total plasma concentration ratios (i.e. [CNS]/[total plasma]) for steps 1-5 ranged from 0.4-0.5. However, average steady-state [CNS]/[free plasma] ratios ranged from 2-3, suggesting active transport of DPHM into the CNS. Plasma protein binding averaged 86.1±2.3% (mean±SD) and was not altered with increasing drug dose. Plasma, CSF, and ECF demonstrated biexponential pharmacokinetics with terminal elimination half lives (t1/2{beta}) of 10.8 ± 5.4, 3.6 ± 1.0, and 5.3 ± 4.2 h respectively. The bulk flow of CSF and transport-mediated efflux of DPHM may explain the observed higher CNS clearances. In the second experiment, DPHM was co-administered with propranolol (PRN) to examine its effect on blood-brain CSF and blood-brain ECF DPHM relationships. Plasma total DPHM concentration decreased by 12.8±6.3% during PRN, whereas ECF and CSF concentrations increased (88.1±45.4 and 91.6±34.3%, respectively). This increase may be due to the inhibitory effect of PRN on a transporter-mediated efflux mechanism for DPHM brain elimination.


Key words: active transport, blood-brain barrier, blood-CNS transport, CNS pharmacokinetics, distribution, excretion, pharmacokinetics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
S. C.S. Au-Yeung, K. W. Riggs, N. Gruber, and D. W. Rurak
The Use of Microdialysis for the Study of Drug Kinetics: Central Nervous System Pharmacokinetics of Diphenhydramine in Fetal, Newborn, and Adult Sheep
Drug Metab. Dispos., August 1, 2007; 35(8): 1285 - 1291.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.